Study to Investigate Blood Samples Drawn With the HemoIV System

NCT ID: NCT06415058

Last Updated: 2025-06-12

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 19 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-05-02
• Study Completion Date: 2025-02-21

Brief Summary

The goal of this study is to compare blood drawn using a device called HemoIV to standard-of-care blood drawn from a vein in the arm or from an IV catheter. The HemoIV is a device that is attached to an IV line. This device allows for blood to be drawn while a patient is receiving IV fluids.

The main questions it aims to answer are:

• Will the HemoIV device allow blood to be drawn without having to stop IV fluids?
• Will the HemoIV device provide the same laboratory results as blood draws done by current standard practice?

Participants will:

• Receive standard medical procedures and/or treatment;
• Have a HemoIV device inserted into their IV line in one arm;
• Have an blood drawn twice from the HemoIV and from an IV line or needle stick from a vein in the other arm. The second blood draw will be done about 8-22 hours after the first blood draw;
• Have the device removed after the second blood draw;
• Receive a phone call about 8 days later to see how you are doing.

Detailed Description

The HemoIV investigational device allows for continuous administration of intravenous fluids for blood draw sampling without exposing patients to additional needle sticks, stoppage of intravenous therapy, and potential exposure to bacteria that are inherent risks when performing blood draws using traditional phlebotomy methods. The purpose of this study is to demonstrate the safety and effectiveness of the HemoIV system.

Participants serve as their own control to compare blood measurement parameters. Blood measurements extracted from the participant will be used to compare the control blood sample(s) to the HemoIV blood sample(s). The contralateral arm to the placement of the HemoIV will be the control arm of the study. It is hypothesized that the HemoIV will provide blood samples within the equivalency margin, compared to standard practice (Venipuncture or Peripheral IV Catheter).

The main objectives are:

• To quantitatively measure and compare blood samples drawn with the HemoIV system during continuous intravenous infusion to blood samples from the contralateral arm to demonstrate safety and efficacy of the HemoIV system
• To quantitatively measure and compare the potential advantages of HemoIV to Venipuncture or Peripheral IV Catheter blood draws

Participant population will consist of adult patients admitted to the hospital for a medical condition in the emergency department, inpatient, or observation units and are requiring blood draws as well as intravenous fluids.

Participants will:

• Receive standard of care intravenous therapy via HemoIV inserted through an established peripheral IV catheter
• Have blood samples obtained twice over a 24 hour period from the HemoIV and from an IV line or standard venipuncture from the contralateral arm
• The second blood sampling will occur approximately 8-22 hours after the first blood sampling
• The HemoIV device will be removed one hour after the second blood sampling occurs
• Participants will be called 8 days later to assess for adverse events

Quality control (QC) procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.

Conditions

Measurement of Blood Parameter Equivalency

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

HemoIV Blood Sampling

Measurement of protocol specified blood parameters drawn from the HemoIV system

HemoIV

Intervention Type: DEVICE

A sterile, single use device. It is a non-patient stick blood collection device that attaches to a peripheral IV catheter (PIV catheter) and allows for blood sample collection to occur during continuous IV infusion therapy. The control blood sampling will occur via standard of care blood draws either through peripheral IV catheter or standard venipuncture.

Control Blood Sampling

Measurement of protocol specified blood parameters drawn from the contralateral control arm

No interventions assigned to this group

Interventions

HemoIV

A sterile, single use device. It is a non-patient stick blood collection device that attaches to a peripheral IV catheter (PIV catheter) and allows for blood sample collection to occur during continuous IV infusion therapy. The control blood sampling will occur via standard of care blood draws either through peripheral IV catheter or standard venipuncture.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 18 and older
• Willing to adhere to the HemoIV intervention regimen
• Patient scheduled for a hospital procedure for medical condition requiring peripheral intravenous catheter placement, intravenous therapy, and blood draw
• Patients to receive intravenous therapy including: Normal Saline, Lactate Ringer, or 5% Dextrose in Water.
• Patient with peripheral intravenous catheter access vein size > 2 mm in diameter or per investigator discretion able to accept an 18G Peripheral Intravenous Catheter.
• Patient must be able to have a peripheral IV catheter in one arm and can have standard venipuncture blood draws from contralateral arm.
• Patient must be able to have an 18G Peripheral Intravenous Catheter inserted for use with the study device up to 1.88" in length.

Exclusion Criteria

• Do not speak/understand English
• Patients who have a prior history of mastectomy
• Concurrent participation/treatment with another investigational drug or other intervention study.
• Patient with signs and symptoms of thrombophlebitis at the IV site at the time of study enrollment
• Patients receiving chemotherapy, or who have leukemia for example who have fragile formed cellular element
• Patients which are hemodynamically unstable
• Patients requiring blood transfusion via the 18G peripheral IV catheter used with HemoIV
• Patients who are unable to have a peripheral IV catheter on one upper extremity while having the other upper extremity available for blood tests (e.g. subjects must have two arms, not have an AV graft or fistula anticipating dialysis in the near future, etc.)
• Subjects who are not able to have an IV infusion rate adjusted in the HemoIV to between 10-250 mL/hr during blood draws via HemoIV
• Patient with morbid obesity, (BMI > 40)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

MedTG LLC

UNKNOWN

Sponsor Role: collaborator

Vanderbilt University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Brian Bales

Associate Professor, Emergency Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sean Collins, MD, MSCi

Role: STUDY_DIRECTOR

Vanderbilt University Medical Center

Brian Bales, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt University Medical Center

Locations

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

HemoIV

Identifier Type: -

Identifier Source: org_study_id